Biotech entity
Every one of those 1 sits in a single category, clinical-trial. ARC-20 Trial is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Sylvester Comprehensive Cancer Center appears in 1 tracked Biotech story from July 28, 2026.
Last mentioned: Jul 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. ARC-20 Trial is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Sylvester Comprehensive Cancer Center appears in 1 tracked Biotech story from July 28, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sylvester Comprehensive Cancer Center. Shared-story counts are live from our verified record — not editorial picks.
Oral HIF-2α inhibitor casdatifan posted durable responses in the ARC-20 phase 1 trial of 127 heavily pretreated ccRCC patients, published in Nature. The data intensifies competition in the HIF-2α space, where Merck’s belzutifan is already approved, and sets the stage for pivotal trials.
Source: miragenews.com · news-medical.net
Sylvester Comprehensive Cancer Center is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
